Transaminase polypeptides

Patent metadata

Field	Value
Publication number	US-2026028600-A1
Application number	US-202519352911-A
Country	US
Kind code	A1
Filing date	Oct 8, 2025
Priority date	Jan 8, 2009
Publication date	Jan 29, 2026
Grant date	—

Abstract

The present disclosure provides engineered transaminase enzymes having improved properties as compared to a naturally occurring wild-type transaminase enzyme. Also provided are polynucleotides encoding the engineered transaminase enzymes, host cells capable of expressing the engineered transaminase enzymes, and methods of using the engineered transaminase enzymes to synthesize a variety of chiral compounds.

First claim

What is claimed is:

1 . An engineered transaminase polypeptide, wherein said transaminase polypeptide comprises a polypeptide sequence at least 90% identical to SEQ ID NO: 2, and wherein the transaminase polypeptide comprises a substitution at one or more positions selected from the group consisting of X417, X317, X85, X314, X318, X320, X319, X409, X166, X434, X44, X12, and X82.

2 . The engineered transaminase polypeptide of claim 1 , wherein said polypeptide has at least about 10% residual activity in the conversion of pyruvate to L-alanine in presence of amino donor isopropylamine after treatment of the polypeptide at 50° C. for 23 h.

3 . The engineered transaminase polypeptide of claim 1 , wherein the transaminase polypeptide has increased transaminase activity as compared to SEQ ID NO: 2 for conversion of an amino acceptor substrate to the corresponding chiral amino product.

4 . The engineered transaminase polypeptide of claim 1 , wherein the transaminase polypeptide sequence comprises one or more substitutions selected from: X417 is A, C, E, F, I, N, Q, Y, S, T, or V; X317 is L, M, or Y; X85 is A, C, S, N, T, G, or V; X314 is T or V; X318 is G, F, C, K, W, or R; X320 is A or K; X319 is Q, G, M, N, or V; X409 is G; X166 is S; X434 is V; X44 is A; X12 is K; and X82 is H.

5 . The engineered transaminase polypeptide of claim 3 , wherein the transaminase polypeptide sequence further comprises at least one additional substitution at a residue position selected from the group consisting of: X4, X12, X21, X44, X45, X57, X82, X85, X86, X157, X166, X177, X208, X211, X233, X253, X272, X294, X302, X314, X316, X317, X318, X319, X320, X324, X391, X398, X409, X417, X418, X420, X431, X434, X444, and X446.

6 . The engineered transaminase polypeptide of claim 3 , wherein the transaminase polypeptide sequence further comprises at least one substitution selected from the group consisting of: X4 is R, Q, or L; X12 is K; X21 is N; X45 is H; X30 is A; X31 is A; X44 is A; X56 is V; X57 is, A, C, F, I, L, or S; X81 is D; X82 is H; X85 is A, C, S, N, T, G, or V; X86 is Y; X95 is T; X112 is I; X113 is C or H; X127 is L; X147 is G; X153 is A, C, G, N, M, Q, S, or T; X166 is S; X157 is T; X177 is L; X181 is R; X208 is I; X211 is K; X228 is G or T; X233 is L, S, I, V, N, G, or T; X253 is M; X272 is A; V297 is A, S, T, I, M, Q, C, or G; X302 is K; X311 is V; X314 is T or V; X316 is K; X317 is L, M, or Y; X318 is G, F, C, K, W, or R; X319 is Q, G, M, N, or V, X320 is A or K; X321 is L, M, or I; X385 is R; X398 is R; X407 is S; X408 is A; X409 is G; X415 is M; X417 is A, C, E, F, I, N, Q, Y, S, T, or V; X418 is V; X420 is N; X431 is D; X434 is V; X438 is L; X444 is V; and X446 is V.

7 . The engineered transaminase polypeptide of claim 3 , wherein the transaminase polypeptide sequence further comprises at least one substitution set selected from the group consisting of: X12 is G and X434 is V; X44 is A and X166 is S; X57 is I and X153 is S; X81 is D and X86 is H; X82 is H and X417 is F; X85 is A and X317 is L; X85 is S and X153 is A; X85 is A and X153 is A; X85 is S and X153 is S; X86 is S and X153 is S; X86 is H and X153 is A; X112 is I and X317 is L; X113 is H and X407 is S; X153 is S and X233 is S; X311 is V and X314 is T; X314 is V and X409 is G; and X318 is G and X408 is A.

8 . The engineered transaminase polypeptide of claim 3 , wherein the transaminase polypeptide sequence further comprises at least one substitution set selected from the group consisting of: X57 is A, X153 is S and X318 is G; X57 is F, X86 is H and X153 is Q; X57 is I, X86 is F and X320 is A; X57 is F, X86 is F and X153 is Q; X57 is A, X153 is C and X321 is L; X57 is C, X86 is S and X417 is T; X57 is C, X86 is A and X317 is L; X57 is F, X318 is F and X417 is S; X57 is L, X86 is S and X153 is A; X57 is F, X318 is G and X417 is I; X57 is L, X86 is F and X318 is F; X57 is L, X417 is C and X438 is L; X57 is F, X127 is L and X417 is C; X57 is S, X233 is L and X417 is V; X57 is S, X86 is G and X417 is C; X85 is A, X147 is G and X153 is A; X85 is S, X153 is A and X233 is T; X85 is A, X153 is S and X417 is S; X86 is H, X153 is A and X417 is C; X86 is H, X153 is S and X417 is C; X86 is F, X153 is C and X297 is A; X86 is S, X153 is T and X297 is A; X86 is H, X233 is L and X417 is A; X86 is F, X318 is R and X417 is A; X86 is N, X228 is G and X317 is L; X95 is T, X153 is A and X417 is C; X113 is C, X385 is R and X417 is C; X153 is A, X317 is L and X318 is G; X153 is A, X233 is T and X417 is C; X153 is S, X318 is R and X417 is E; X153 is C, X233 is L and X318 is R; X153 is T, X228 is G and X321 is L; X153 is S, X317 is L and X417 is C; X153 is T, X319 is V and X417 is I; X153 is S, X228 is G and X417 is V; X153 is C, X317 is Y and X319 is Q; X153 is T, X228 is G and X417 is A; X228 is G, X317 is L and X417 is C; X228 is G, X318 is G and X417 is C; X233 is L, X321 is L and X417 is I; and X317 is L, X318 is R and X417 is T.

9 . The engineered transaminase polypeptide of claim 3 , wherein the transaminase polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, and 192.

11 . The engineered transaminase polypeptide of claim 1 , wherein the transaminase polypeptide is capable of converting the amino acceptor substrate to the corresponding amino product with improved R-enantioselectivity as compared to SEQ ID NO: 18.

12 . The engineered transaminase polypeptide of claim 11 , wherein the transaminase polypeptide sequence further comprises at least one substitution selected from the group consisting of: X57 is L, X81 is D, X82 is H, X85 is A, C, N, T, or V; X95 is T; X112 is I; X147 is G; X153 is A, S, N, G, or T; X233 is S or T; X317 is L, X318 is G or R; and X319 is V.

13 . The engineered transaminase polypeptide of claim 11 , wherein the transaminase polypeptide sequence further comprises at least one substitution or substitution set selected from the group consisting of: X85 is A; X85 is A and X153 is A; and X85 is S and X153 is A.

14 . The engineered transaminase polypeptide of claim 11 , wherein the transaminase polypeptide sequence is selected from the group consisting of SEQ ID NO: 22, 30, 32, 34, 36, 40, 44, 48, 56, 58, 60, 62, 64, 66, 68, 70, 72, 76, 84, 88, 90, 92, 104, 108, 110, 120, 122, 124, 126, 128, 132, 160, and 176.

15 . The engineered transaminase polypeptide of claim 1 , wherein the transaminase enzyme polypeptide is capable of converting an amino acceptor substrate selected from 3,4-dihydronaphthalen-1(2H)-one, 1-phenylbutan-2-one, 3,3-dimethylbutan-2-one, octan-2-one, ethyl 3-oxobutanoate, 4-phenylbutan-2-one, and 1-(4-bromophenyl)ethanone to the corresponding amine product at a rate that is greater than the polypeptide of SEQ ID NO: 2 or 18.

16 . The engineered transaminase polypeptide of claim 15 , wherein the transaminase polypeptide sequence comprises at least one additional substitution or substitution set selected from the group consisting of: X30 is A; X31 is A; X57 is I; X82 is H; X85 is V; X85 is C; X153 is S; X177 is L; X317 is M; X317 is Y; X417 is A; X319 is Q; X320 is A; X417 is I; X113 is H and X407 is S; X44 is A and X166 is S; X314 is V and X409 is G; X153 is S and X233 is S; X311 is V and X314 is T; X153 is S, X318 is R and X417 is E;

Assignees

• Codexis Inc

Inventors

• Dhawan Ish K
• Miller Gregory
• Zhang Xiyun

Classifications

• Y02P20/52

  using catalysts, e.g. selective catalysts · CPC title

• C12Y206/01018

  Beta-alanine-pyruvate transaminase (2.6.1.18) · CPC title

• C12Y206/01

  Transaminases (2.6.1) · CPC title

• C12P41/006

  by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures · CPC title

• C12P13/001

  Amines; Imines · CPC title